|
|
Article: CSL Limited to Apply for License to Market Influenza Vaccine in the U.S.; Major Vaccine Manufacturer to Double Capacity.
- Article from:
- Business Wire
- Article date:
- February 7, 2006
CopyrightCOPYRIGHT 2006 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
NEW YORK -- CSL Limited (ASX: CSL), a global, specialty biopharmaceutical company headquartered in Melbourne, Australia, today announced plans to introduce its influenza vaccine into the U.S. market.
Speaking at Merrill Lynch's Global Pharmaceutical and Biotechnology Conference here, CSL Chief Executive Officer and Managing Director Dr. Brian McNamee said, "CSL is the leading producer of influenza vaccine in the Southern Hemisphere and has a long heritage in biological research and manufacture. With the planned expansion of our influenza vaccine production capabilities, we look forward to working with the Food and Drug Administration (FDA) on the licensing of our ...
Related newspaper, magazine, and journal articles:
|
|
Article: U.S. FDA Licenses CSL Biotherapies' New U.S. Influenza ...
Vaccine Weekly;
September 2, 2009 ;
700+ words
... ... subsidiary of CSL Limited, one of the ... manufacturers of influenza vaccine, announced ... countries. CSL's influenza vaccine is a purified ... trivalent influenza vaccine propagated ... sponsored by CSL Limited, and a clinical ...
|
|